Patient characteristics at baseline
Characteristics . | Patients* . |
|---|---|
| Median age, y (range) | 48 (17-76) |
| Sex, no. (%) | |
| Male | 37 (54.4) |
| Female | 31 (45.6) |
| Disease status, no. (%) | |
| First relapse | 28 (41) |
| Second or later relapse | 13 (19) |
| Primary refractory | 25 (37) |
| CR1 | 2 (3) |
| Subtype of ALL, no. (%) | |
| c-ALL | 49 (72) |
| Pre-B-ALL | 14 (21) |
| Biphenotypic | 2 (3) |
| NA | 3 (4) |
| p190Bcr-Abl vs. p210Bcr-Abl, no. (%) | |
| M-Bcr-Abl† | 18 (26.5) |
| m-Bcr-Abl‡ | 49 (72) |
| NA | 1 (1.5) |
| Karyotype, no. (%) | |
| Complex karyotype | 22 (43)§ |
| At least 2 Ph-chromosomes in cytogenetic or FISH analysis | 23 (36)∥ |
| No. of prior chemotherapy cycles, median (range) | 3 (1-10) |
| Prior CNS irradiation, no. (%) | 29 (43) |
| Prior infectious complications of grade III or IV, no. (%) | |
| Fungal infections | 13 (19) |
| Septicemia | 12 (18) |
| Prior SCT, no. (%) | |
| Allogeneic | 20 (29) |
| Autologous | 4 (6) |
| Median time from diagnosis to study entry, mo (range) | 7 (2-66) |
| Median duration of CR1, mo (range) | 7 (1-44) |
| Median WBC count, × 109/L (range) | 6.1 (0.2-176) |
| WBC count of at least 10 × 109/L, no. (%) | 24 (35.3) |
| Median % of blasts in peripheral blood (range) | 10 (0-90) |
| Blasts in peripheral blood, no. (%) | 41 (60.3) |
| Median % of blasts in bone marrow (range) | 84 (5-99) |
| Median platelets, × 109/L (range) | 63 (11-472) |
Characteristics . | Patients* . |
|---|---|
| Median age, y (range) | 48 (17-76) |
| Sex, no. (%) | |
| Male | 37 (54.4) |
| Female | 31 (45.6) |
| Disease status, no. (%) | |
| First relapse | 28 (41) |
| Second or later relapse | 13 (19) |
| Primary refractory | 25 (37) |
| CR1 | 2 (3) |
| Subtype of ALL, no. (%) | |
| c-ALL | 49 (72) |
| Pre-B-ALL | 14 (21) |
| Biphenotypic | 2 (3) |
| NA | 3 (4) |
| p190Bcr-Abl vs. p210Bcr-Abl, no. (%) | |
| M-Bcr-Abl† | 18 (26.5) |
| m-Bcr-Abl‡ | 49 (72) |
| NA | 1 (1.5) |
| Karyotype, no. (%) | |
| Complex karyotype | 22 (43)§ |
| At least 2 Ph-chromosomes in cytogenetic or FISH analysis | 23 (36)∥ |
| No. of prior chemotherapy cycles, median (range) | 3 (1-10) |
| Prior CNS irradiation, no. (%) | 29 (43) |
| Prior infectious complications of grade III or IV, no. (%) | |
| Fungal infections | 13 (19) |
| Septicemia | 12 (18) |
| Prior SCT, no. (%) | |
| Allogeneic | 20 (29) |
| Autologous | 4 (6) |
| Median time from diagnosis to study entry, mo (range) | 7 (2-66) |
| Median duration of CR1, mo (range) | 7 (1-44) |
| Median WBC count, × 109/L (range) | 6.1 (0.2-176) |
| WBC count of at least 10 × 109/L, no. (%) | 24 (35.3) |
| Median % of blasts in peripheral blood (range) | 10 (0-90) |
| Blasts in peripheral blood, no. (%) | 41 (60.3) |
| Median % of blasts in bone marrow (range) | 84 (5-99) |
| Median platelets, × 109/L (range) | 63 (11-472) |